Institute of Experimental Hematology and Transfusion Medicine, University of Bonn, Bonn, Germany.
Clin Chem Lab Med. 2020 Jun 29;58(12):2081-2087. doi: 10.1515/cclm-2020-0014.
Objectives Analysis of platelet glycoprotein (GP) expression by flow cytometry is applied for diagnostic confirmation of GP-associated thrombocytopathies. While platelet-rich plasma may be used for distinct identification of target events, this strategy is not feasible for small sample volumes or for patients showing low platelet counts and/or giant platelets. However, also the use of whole blood (WB) is hampered by the difficulty to discriminate platelets from red blood cells (RBC) in such patients. To circumvent these limitations, we evaluated the feasibility of a RBC gating-out strategy. Methods In addition to platelet GPIb, GPIIa/IIIa, as well as P-selectin (CD62P), citrated whole blood (CWB) samples were stained for RBC-specific glycophorin A (CD235a). CD235a-negative platelet events were further discriminated by forward-/side-scatter characteristics and platelet GP expressions analyzed relative to that of a healthy control sample processed in parallel. Results Established reference intervals allowed for clear identification of decreased GPIIb/IIIa- or GPIb expression pattern in samples of patients with confirmed Glanzmann thrombasthenia or Bernard-Soulier syndrome, respectively. It could be shown that the analysis of 2,500 platelet events is sufficient for reliable GP expression analysis, rendering the proposed method applicable to samples with low platelet counts. Conclusions This study demonstrates the feasibility of CD235a-based exclusion of RBC for platelet GP expression analysis in CWB. In contrast to direct staining of platelet-specific antigens for target identification, this indirect gating out approach is generally applicable independent of any underlying platelet GP expression deficiency.
目的 通过流式细胞术分析血小板糖蛋白 (GP) 的表达,可用于诊断与 GP 相关的血小板病。虽然富血小板血浆可用于明确识别靶事件,但对于小样本量或血小板计数低和/或巨大血小板的患者,这种策略不可行。然而,由于在这些患者中难以区分血小板和红细胞 (RBC),因此也无法使用全血 (WB)。为了规避这些限制,我们评估了 RBC 排除策略的可行性。
方法 除了血小板 GPIb、GPIIa/IIIa 以及 P-选择素 (CD62P) 外,枸橼酸盐全血 (CWB) 样本还针对 RBC 特异性糖蛋白 A (CD235a) 进行染色。通过前向/侧向散射特征进一步区分 CD235a 阴性血小板事件,并相对于平行处理的健康对照样本分析血小板 GP 表达。
结果 既定的参考区间允许明确识别出确诊的 Glanzmann 血小板无力症或 Bernard-Soulier 综合征患者样本中 GPIIb/IIIa 或 GPIb 表达模式降低。结果表明,分析 2500 个血小板事件足以进行可靠的 GP 表达分析,从而使该方法适用于血小板计数低的样本。
结论 本研究证明了基于 CD235a 的 RBC 排除在 CWB 中进行血小板 GP 表达分析的可行性。与直接针对血小板特异性抗原进行靶识别的方法相比,这种间接排除方法通常适用于任何潜在血小板 GP 表达缺陷的情况下。